Therefore, our results indicate the function of the TRAF6/IRF3 axis in 5-FU-resistant GC cells, and TRAF6 is poised to become an attractive therapeutic target to alleviate chemoresistance in GC. The gene discussed is TRAF6; the disease is gastric cancer.